Cargando…
Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
Clinical trials that have a pharmacokinetic or a pharmacodynamic immunologic mechanism of action–based primary outcome could substantially improve the validity and efficiency of early development of immuno-oncology agents. Here, we outline different trial design options in this area, review examples...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Association for Cancer Research
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738124/ https://www.ncbi.nlm.nih.gov/pubmed/34312214 http://dx.doi.org/10.1158/1078-0432.CCR-21-1593 |